Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Octreotide × NET × Clear all

Phase

Status

Sponsor Class

OTHER 6 INDUSTRY 5 NIH 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2 Endocrine 2 Thoracic 1 NET 1 CNS 1 Breast 1

Conditions

Vipoma 1 Somatostatinoma 1 Neuroendocrine Tumors 1 Neoplasms 1 Insulinoma 1 Glucagonoma 1 Gastrinoma 1 Carcinoma, Islet Cell 1 Adenoma, Islet Cell 1

Interventions

motesanib diphosphate 1 batifiban 1 Octreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed

46 enrolled 7 charts

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡